The EPO issued Patent EP3526334A1 to Regeneron Pharmaceuticals covering endonuclease variants targeting the TGFBETAR2 gene, along with related compositions and therapeutic methods. The patent application was filed by inventors Jarjour and Havens and covers molecular constructs and methods for gene editing applications in the designated contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).

Pharmaceutical and biotechnology companies developing gene editing therapies, particularly those targeting TGF-beta signaling pathways, should conduct freedom-to-operate analyses to assess potential infringement risks. Competitors should evaluate whether their therapeutic candidates fall within the scope of the granted claims. No immediate compliance action is required, but strategic IP planning should account for this newly granted patent in European markets.